Skip to content.

AstraZeneca agrees to acquire Alexion Pharmaceuticals, Inc. for US$39B

Date Closed

July 21, 2021

Lead Office



39.00 Billion USD

On July 21, 2021, AstraZeneca closed its agreement with Alexion Pharmaceuticals, Inc. to acquire Alexion for a total consideration of US$39 billion in cash and stock. The deal was undertaken through a US statutory merger. Upon completion, Alexion shareholders own approximately 15% of the combined company.

The acquisition will be financed in part by bridge financing provided by Morgan Stanley, J.P. Morgan Securities plc and Goldman Sachs.

AstraZeneca is a global biopharmaceutical company, based in the UK, that focuses on treatments and medical advancements in Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

McCarthy Tétrault advised AstraZeneca as Canadian competition counsel with a team led by Jason Gudofsky that included Casey Halladay and Jonathan Bitran (Competition) and Lisa Melanson (Regulatory).